0001237899-18-000016.txt : 20180928
0001237899-18-000016.hdr.sgml : 20180928
20180928163554
ACCESSION NUMBER: 0001237899-18-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180927
FILED AS OF DATE: 20180928
DATE AS OF CHANGE: 20180928
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BROWN MICHAEL S
CENTRAL INDEX KEY: 0001174475
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 181094590
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-09-27
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001174475
BROWN MICHAEL S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2018-09-27
4
M
0
2000
273.67
A
2000
D
Common Stock
2018-09-27
4
S
0
389
390.23
D
1611
D
Common Stock
2018-09-27
4
S
0
601
391.38
D
1010
D
Common Stock
2018-09-27
4
S
0
410
392.37
D
600
D
Common Stock
2018-09-27
4
S
0
300
393.49
D
300
D
Common Stock
2018-09-27
4
S
0
40
394.43
D
260
D
Common Stock
2018-09-27
4
S
0
260
395.42
D
0
D
Common Stock
5000
I
by SLAT
Common Stock
12349
I
by Trust
Non-Qualified Stock Option (right to buy)
273.67
2018-09-27
4
M
0
2000
0.0
D
2024-01-02
Common Stock
2000
10750
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 389 shares of Company stock on September 27, 2018 at prices ranging from $390.00 to $390.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
Represents volume-weighted average price of sales of 601 shares of Company stock on September 27, 2018 at prices ranging from $391.00 to $391.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
Represents volume-weighted average price of sales of 410 shares of Company stock on September 27, 2018 at prices ranging from $392.00 to $392.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
Represents volume-weighted average price of sales of 300 shares of Company stock on September 27, 2018 at prices ranging from $393.41 to $393.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
Represents volume-weighted average price of sales of 260 shares of Company stock on September 27, 2018 at prices ranging from $395.18 to $395.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Michael S. Brown
2018-09-28